Orum Therapeutics

📍 Daejeon, Korea & Lexington, MA, USA, United States🗓 Founded 2016👥 53 employees💰 Last funded Jan 2026
Biotechnology Research🌐 orumrx.com
Website LinkedIn
Orum Therapeutics (KRX: 475830) is a public biotechnology company developing TPD2®, a novel class of targeted protein degradation therapeutics. Also known as degrader-antibody conjugates (DACs), these therapeutics combine the precision of antibodies with Orums novel degrader payloads to break down disease-causing proteins inside specific cells. By enabling the selective degradation of previously “undruggable” targets, Orum is working to improve the effectiveness, safety, and reach of targeted protein degradation. The company’s lead programs target GSPT1, and it is also advancing next-generation payloads to expand the potential of its DAC pipeline. In parallel, Orum is developing proprietary linker technologies to increase the flexibility and precision of future DAC programs. With headquarters in Daejeon, South Korea, and Lexington, Massachusetts, U.S., Orum is globally positioned to deliver first-in-class cancer therapies for patients with hard-to-treat diseases. For more information, visit www.orumrx.com.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Korea
1
Frequently asked questions
Who invested in Orum Therapeutics?
Orum Therapeutics has 1 investors on record on gritt.io and 1 late-stage investors.
When did Orum Therapeutics last raise funding?
The most recent investment in Orum Therapeutics recorded on gritt.io was in January 2026.
When was Orum Therapeutics founded?
Orum Therapeutics was founded in 2016.
What industry is Orum Therapeutics in?
Orum Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Orum Therapeutics based?
Orum Therapeutics is headquartered in Daejeon, Korea & Lexington, MA, USA, United States.